LGG conferred protection against DON/ZEA by regulation of MUC2 and intestinal TFF3.
LGG improved DON/ZEA-induced plasma d-lactate and IL8/CXCL8 levels.
LGG improved DON/ZEA-induced serum IgA, IgM and IgG dysregulation.
LGG partially prevented or treated the unwanted adverse effects of DON/ZEA.